BioSpace News Archive

In a recent op-ed in Fortune, Joe Biden expounded upon his call to improve access to healthcare information for patients.

Allecra Therapeutics announced positive top-line results from the Phase 2 study of its lead antibiotic candidate, an extended spectrum β-lactamase inhibitor known as AAI101.

Evotec AG has launched its accelerated drug development service INDiGO(R).

Biohaven Pharmaceutical Holding Company Ltd. announced positive top-line results from both of its two Phase 3 clinical trials (BHV3000-301 and BHV3000-302) of rimegepant (formerly known as BHV-3000), an oral CGRP receptor antagonist for the acute treatment of migraine.

Protagonist Therapeutics, Inc. announced that the Company is discontinuing the Phase 2b PROPEL study of PTG-100, its investigational oral GI-restricted alpha-4-beta-7 integrin antagonist peptide, in patients with moderate to severe ulcerative colitis (UC).

Flex Pharma Inc. announced positive topline data for FLX-787 from its exploratory Phase 2 trial in MS patients with frequent muscle cramps/spasms and spasticity.

Seattle Genetics, Inc. (NASDAQ: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate (ADC), for patients with locally advanced or metastatic urothelial cancer who were previously treated with checkpoint inhibitors (CPI).

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has refinanced its existing $1.0 billion of revolving credit facility due 2021 with a new $1.55 billion revolving credit facility due 2023, and its existing $650.0 million of term loan facility due 2021 with a new $750.0 million term loan facility due 2023 (the “credit facilities”).

Gum tissue repairs itself roughly twice as fast as skin and with reduced scar formation.

Patients Experienced Clinically Meaningful Reduction in Pain AmnioFix Injectable Achieves Primary and Secondary Efficacy Endpoints Statistically Significant Difference in Pain and Function Compared to Placebo